MA35362B1 - Nouvelle forme de cristal - Google Patents
Nouvelle forme de cristalInfo
- Publication number
- MA35362B1 MA35362B1 MA36784A MA36784A MA35362B1 MA 35362 B1 MA35362 B1 MA 35362B1 MA 36784 A MA36784 A MA 36784A MA 36784 A MA36784 A MA 36784A MA 35362 B1 MA35362 B1 MA 35362B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystal form
- new crystal
- new
- compound
- relates
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Glass Compositions (AREA)
Abstract
L'invention porte sur une nouvelle forme cristallisée d'un composé.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530104P | 2011-09-01 | 2011-09-01 | |
| PCT/EP2012/067027 WO2013030374A1 (fr) | 2011-09-01 | 2012-08-31 | Nouvelle forme de cristal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35362B1 true MA35362B1 (fr) | 2014-08-01 |
Family
ID=46829730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36784A MA35362B1 (fr) | 2011-09-01 | 2014-02-28 | Nouvelle forme de cristal |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9227953B2 (fr) |
| EP (1) | EP2751094B1 (fr) |
| JP (1) | JP6199291B2 (fr) |
| KR (2) | KR20140056297A (fr) |
| CN (1) | CN103906744A (fr) |
| AU (2) | AU2012300841C1 (fr) |
| BR (1) | BR112014004251A2 (fr) |
| CA (1) | CA2847066C (fr) |
| CL (1) | CL2014000489A1 (fr) |
| CO (1) | CO6890102A2 (fr) |
| CR (1) | CR20140098A (fr) |
| CY (1) | CY1120784T1 (fr) |
| DK (1) | DK2751094T3 (fr) |
| DO (1) | DOP2014000042A (fr) |
| EA (1) | EA027972B1 (fr) |
| ES (1) | ES2686563T3 (fr) |
| HR (1) | HRP20181375T1 (fr) |
| HU (1) | HUE041578T2 (fr) |
| IL (1) | IL230977A (fr) |
| LT (1) | LT2751094T (fr) |
| MA (1) | MA35362B1 (fr) |
| MX (1) | MX349243B (fr) |
| MY (1) | MY172885A (fr) |
| PE (1) | PE20141411A1 (fr) |
| PH (1) | PH12014500382A1 (fr) |
| PL (1) | PL2751094T3 (fr) |
| PT (1) | PT2751094T (fr) |
| RS (1) | RS57644B1 (fr) |
| SG (1) | SG2014011886A (fr) |
| SI (1) | SI2751094T1 (fr) |
| SM (1) | SMT201800455T1 (fr) |
| UA (1) | UA114607C2 (fr) |
| WO (1) | WO2013030374A1 (fr) |
| ZA (1) | ZA201401176B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227953B2 (en) * | 2011-09-01 | 2016-01-05 | Glaxo Group Limited | Crystal form |
| EP2764866A1 (fr) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibiteurs de l'enzyme activant nedd8 |
| BR112022017437A2 (pt) * | 2020-03-30 | 2022-10-18 | Jiangsu Yahong Meditech Co Ltd | Forma de cristal do pró-fármaco de nitroxolina, composição farmacêutica contendo o mesmo, e método de preparação e aplicação do mesmo |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO1993025190A1 (fr) | 1992-06-10 | 1993-12-23 | Eastman Kodak Company | Nanoparticules de medicaments anti-inflammatoires non steroidiens modifiees en surface |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| WO1998035666A1 (fr) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Preparation de pastilles de naproxene nanoparticulaire |
| GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| US9029383B2 (en) * | 2007-05-11 | 2015-05-12 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| BRPI0721697A2 (pt) * | 2007-05-11 | 2014-08-05 | Univ Jefferson | " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2." |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| WO2008140450A1 (fr) * | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Méthodes de traitement et de prévention de maladies et de troubles osseux métaboliques |
| EP2619203A4 (fr) | 2010-09-20 | 2014-04-16 | Glaxo Group Ltd | Composés tricycliques, leurs procédés de préparation et leurs utilisations |
| WO2012075917A1 (fr) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Composés |
| US8637536B2 (en) | 2010-12-06 | 2014-01-28 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
| EP2651403B1 (fr) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Procédés de traitement et de prévention de maladies oculaires |
| US9227953B2 (en) * | 2011-09-01 | 2016-01-05 | Glaxo Group Limited | Crystal form |
| EP2764866A1 (fr) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibiteurs de l'enzyme activant nedd8 |
-
2012
- 2012-08-31 US US14/241,913 patent/US9227953B2/en not_active Expired - Fee Related
- 2012-08-31 HU HUE12756693A patent/HUE041578T2/hu unknown
- 2012-08-31 KR KR1020147005011A patent/KR20140056297A/ko not_active Ceased
- 2012-08-31 MY MYPI2014700470A patent/MY172885A/en unknown
- 2012-08-31 PL PL12756693T patent/PL2751094T3/pl unknown
- 2012-08-31 SG SG2014011886A patent/SG2014011886A/en unknown
- 2012-08-31 JP JP2014527685A patent/JP6199291B2/ja not_active Expired - Fee Related
- 2012-08-31 WO PCT/EP2012/067027 patent/WO2013030374A1/fr not_active Ceased
- 2012-08-31 BR BR112014004251A patent/BR112014004251A2/pt not_active Application Discontinuation
- 2012-08-31 ES ES12756693.3T patent/ES2686563T3/es active Active
- 2012-08-31 MX MX2014002454A patent/MX349243B/es active IP Right Grant
- 2012-08-31 SM SM20180455T patent/SMT201800455T1/it unknown
- 2012-08-31 SI SI201231371T patent/SI2751094T1/sl unknown
- 2012-08-31 UA UAA201403151A patent/UA114607C2/uk unknown
- 2012-08-31 HR HRP20181375TT patent/HRP20181375T1/hr unknown
- 2012-08-31 PT PT12756693T patent/PT2751094T/pt unknown
- 2012-08-31 EP EP12756693.3A patent/EP2751094B1/fr active Active
- 2012-08-31 DK DK12756693.3T patent/DK2751094T3/en active
- 2012-08-31 KR KR1020197017797A patent/KR20190075172A/ko not_active Ceased
- 2012-08-31 CA CA2847066A patent/CA2847066C/fr not_active Expired - Fee Related
- 2012-08-31 PH PH1/2014/500382A patent/PH12014500382A1/en unknown
- 2012-08-31 CN CN201280051671.XA patent/CN103906744A/zh active Pending
- 2012-08-31 LT LTEP12756693.3T patent/LT2751094T/lt unknown
- 2012-08-31 RS RS20181064A patent/RS57644B1/sr unknown
- 2012-08-31 EA EA201490536A patent/EA027972B1/ru not_active IP Right Cessation
- 2012-08-31 AU AU2012300841A patent/AU2012300841C1/en not_active Ceased
- 2012-08-31 PE PE2014000274A patent/PE20141411A1/es not_active Application Discontinuation
-
2014
- 2014-02-13 IL IL230977A patent/IL230977A/en active IP Right Grant
- 2014-02-17 ZA ZA2014/01176A patent/ZA201401176B/en unknown
- 2014-02-27 CL CL2014000489A patent/CL2014000489A1/es unknown
- 2014-02-27 CR CR20140098A patent/CR20140098A/es unknown
- 2014-02-28 MA MA36784A patent/MA35362B1/fr unknown
- 2014-02-28 CO CO14043369A patent/CO6890102A2/es not_active Application Discontinuation
- 2014-02-28 DO DO2014000042A patent/DOP2014000042A/es unknown
-
2015
- 2015-11-25 US US14/951,997 patent/US9682074B2/en not_active Expired - Fee Related
-
2016
- 2016-01-28 AU AU2016200492A patent/AU2016200492B2/en not_active Ceased
- 2016-09-01 US US15/254,160 patent/US9694004B2/en not_active Expired - Fee Related
-
2018
- 2018-09-04 CY CY181100922T patent/CY1120784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| MA35245B1 (fr) | Pyridin-2-amides utiles comme agonistes de cb2 | |
| MX2014001944A (es) | Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c. | |
| EP2894156A4 (fr) | Cristal d'un dérivé dispiropyrrolidine | |
| BR112014029957A2 (pt) | processos para produzir determinados 2-(piridina-3-il)tiazóis | |
| CR20130369A (es) | Novedosos derivados heterocíclicos | |
| UY33735A (es) | Compuestos antivirales | |
| MX2016013735A (es) | Cristales novedosos de compuesto tetraciclico. | |
| CR11161A (es) | Procesos para la produccion de pirazoles | |
| CO6821935A2 (es) | Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos | |
| EP2906531A4 (fr) | Composés utiles pour la synthèse de composés benzamide | |
| MA32215B1 (fr) | Cristal de compose de benzimidazole | |
| BR112013030973A8 (pt) | processo para a preparação de amidas de prostaglandina | |
| MX2014002625A (es) | Nuevas composiciones para la produccion de poliamidas coladas. | |
| EP2940001A4 (fr) | Procédé pour produire une forme purifiée d'un composé d'amine | |
| EP2690204A4 (fr) | Procédé de fabrication d'un cristal de nitrure | |
| CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
| UY34504A (es) | Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3 | |
| EP2708530A4 (fr) | Procédé de synthèse stéréospécifique de composés de trétinoïne | |
| SA114350792B1 (ar) | شكل متبلر جديد من ملح الـبيميرولاست | |
| CY1120784T1 (el) | Νεα κρυσταλλικη μορφη | |
| MX337610B (es) | Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma. | |
| EP2592080A4 (fr) | Cristal d'un sel d'un composé de pyridine fusionné | |
| CU20130092A7 (es) | Nuevo procedimiento para la síntesis de la agomelatina | |
| DK2585182T3 (da) | Fremgangsmåde til fremstilling af farmakologisk rene krystaller |